Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study
Sponsor: National Cancer Institute (NCI)
Summary
This phase IV trial investigates whether one dose of a human papillomavirus vaccine works as well as two doses in preventing human papillomavirus (HPV) infection. Certain types of HPV cause almost all cases of cervical cancer. Vaccines that protect against infection with these types of human papillomavirus may reduce the risk of cervical cancer. Both Gardasil-9 and Cervarix protect against HPV 16 and 18, which cause 70% of all cervical cancers. However, HPV vaccination rates are too low, especially in countries with very high rates of cervical cancer. HPV vaccines are expensive-many countries cannot afford them-more than one dose is needed, and giving multiple doses is difficult. Researchers want to find out if one dose prevents HPV infection. If it does, more people might get the vaccine.
Official title: A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study ("Estudio de Comparacion de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano (VPH)")
Key Details
Gender
FEMALE
Age Range
12 Years - 21 Years
Study Type
INTERVENTIONAL
Enrollment
27945
Start Date
2017-11-29
Completion Date
2028-08-01
Last Updated
2025-09-04
Healthy Volunteers
Yes
Interventions
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Given IM
Questionnaire Administration
Ancillary studies
Recombinant Human Papillomavirus Bivalent Vaccine
Given IM
Recombinant Human Papillomavirus Nonavalent Vaccine
Given IM
Locations (1)
Agencia Costarricense de Investigaciones Biomédicas (ACIB)
Liberia, Guanacaste Province, Costa Rica